Skip to main content
EXEL $64.63 -1.82%
EXEL logo
EXEL · Exelixis, Inc.
Track EXEL — free
Market Cap
$15.77B
Shares
244.01M
Volume · Nov 20 2.19M Avg daily vol (3M) 2.44M
All webcasts

Conference · 2026-11-17

Exelixis, Inc. (EXEL) November 17, 2026 Conference Transcript

Concluded Nov 17, 2026 Audio replay
Nov 17, 2026 30:03 35 turns
Period
2026-11-17
Runtime
30:03
Sources
2 artifacts

Transcript & audio

30:03 Audio
Ash Verma Analyst — UBS

Welcome to UBS Global Biopharma Conference in London. My name is Ash Verma. I coerce Midcap Biotech and Specpharma, and I'm really excited to have Exelexis as the next company. And I have Andrew Peters, who is the SVP of Strategy and Investor Relations. So thank you, Andrew, for joining us.

Andrew Peters Head of Investor Relations

Yeah, thank you for the invite.

Ash Verma Analyst — UBS

Yeah, so this Exelexis has been a pretty incredible story, just like looking at the stock chart. I mean, what a turnaround you've had going from back when you settled on carbometrics and then Zanza, Litnib, and sort of building out the pipeline. Maybe if you can just kind of highlight a couple of key topics in terms of some of the recent updates that you've had from the third quarter earnings, and then we can take it from there.

Andrew Peters Head of Investor Relations

Yeah, great, and thanks again for the invite. I'm happy to be here as an alumnus of UBS myself. Always good to be on the stage in this seat versus that seat. As a reminder, I'm going to be making some forward-looking statements today, so please see relevant disclosures around risks to our business in our filings with the SEC. So, yeah, really exciting time to be at Exalexis. It's kind of that pivot point or turning point for the company is we're transitioning from a single product company with CaboMedics to now a multi-franchise company with Zanzalutinib in our potential approval and Padufa date early next year. You know, one of the things we say all the time, you know, biotech, biopharma is a really tough business. Finding one successful franchise is hard. Doing it a second time is even more difficult, and that's something that I really think we internalize and are particularly proud of and kind of all of the work and excitement that we have internally. So, you know, third quarter call really is kind of about two things, you know, the Cabo business continuing to kind of hum along, and then, you know, Zanza development, Zanza pre-commercial activity, and then kind of our, you know, internal efforts around early pipeline and expense management, expense discipline, and kind of this through line that we run X-Alexis like a business and not a biotech. And that's something that we really take to heart and try and do. So excited times, but our focus is just on execution. We're going to keep our head down and keep going.

Ash Verma Analyst — UBS

Yeah, that's great. So maybe I'll spend a little bit of a few questions on carbometrics first. So I mean, I think there has been a few data sets that have come out, particularly the LightSpark 011 study. And some of the feedback that we've heard from physicians is that so as that regimen starts to get used in more second line, Cabo moves more to earlier line. I mean, is that sort of similar to the dynamic that you're experiencing as well? And just from your vantage point, if you can talk about what's sort of the flow of patients that you would benefit out of this?

Andrew Peters Head of Investor Relations

Yeah, so I think you're referring to the LightSpark 11 data that came out at ESMO earlier this year. And, you know, taking a step back, I think ESMO was great in a sense that there was a lot of data coming out in RCC. And as kind of the market leaders in RCC, it's heartening to see a lot of interest in the space and a lot of kind of the growing, you know, just. Combinations, modalities, all of that stuff is something that we're certainly focused on and paying attention to. So great to see. Some kind of learnings there, I guess, before I talk about LightSpark 11, one of the things in the broader RCC space that we certainly focused on is LightSpark 12 and the failure there. And what that really does is it opens the door for opportunities for XLXs to invest in the frontline. So that's something kind of an area to certainly stay tuned over the next several months as we think about how to kind of implement a strategy there. But your question on LightSpark11 and kind of the second-line dynamic, really the full data set that read out at ESMO was really kind of as expected. They saw a PFS benefit but didn't see a statistically significant survival advantage. And it kind of comes down to one of those age-old questions in oncology where is it better to sequence or is it better to combine? Historically, the way that you answer that question is overall survival. Because if you take a look at, say, CoboMedics or a TK on its own in second line, and then Belzutafan on its own in third line, you're, you know, 10, 11 months, 5, 6 months. So the totality, the absolute PFS of the sequence approach is actually a little bit longer than the combined approach than you layer on the tox and tolerability issues and all of that. So it becomes a real kind of question for patients and physicians in a conversation to have, especially in the context of no overall survival. So that's some of the kind of market backdrop that we expect. The second part is certainly, you know, the case where we talked about, you know, if those patients and physicians are likely to get Len Bell second line means they most likely won't get Len first line. And so that kind of first line market share that we're continuing to fight for every single day in the market, that should probably benefit us. And so again, as all of the data continue to kind of stream out of ESMO, not a lot really changed. You know, we'll probably see some incremental share in first line, depending on if we lose some share second line. So it's kind of, you know, that dynamic is what we're paying attention to. All right.

Ash Verma Analyst — UBS

Okay. And if I can just follow up, so that's an interesting nugget that you could pursue more opportunities in the first line. I mean, is it more for the Cabo or some early stage pipeline?

Andrew Peters Head of Investor Relations

No, no, no, Zanza. So I guess big picture, I mean, the way that we're thinking about it is we have the seven pivotal studies with Zanza right now. We call wave one. And, you know, the totality of those opportunities, we think not only can let us kind of grow through Cabo, but grow, you know, much better than Cabo. And then we're layering on the second wave of Zanza opportunities, which we think have the potential to be much bigger. And so I'd certainly lump that frontline RCC study that we're kind of putting the finishing touches on, so to speak, as one of the key anchor points of that second wave of ZANSA.

Ash Verma Analyst — UBS

Got it. Okay, perfect. And then I know there's been some competitor update under the HIF2 Alpha, Cast Data Fan, didn't really generate the competitive data set in second line RCC. Just like your thoughts on that, curious to see, they have a first line study that's reading out in, you know, 2028. So just curious from your perspective is there could be sort of like a revival of this thesis that there's more competition?

Andrew Peters Head of Investor Relations

Yeah, so the HIF space is certainly one we're focused on. Obviously, we have two pivotal studies that Merck is running with Zanza and Bell's. You know, totality of the data, you know, we tend to see those two molecules as probably more similar than different with Zanza as the kind of best-in-class TKI of choice. I mean, our perspective on the evolution of how RCC patients will be treated in the future is that Cabo is the TKI of choice for the 2020s, and Zanza will be the TKI of choice for the 2030s. And so that's a dynamic that, again, is going to kind of flow through one studies, but the wave two studies as well as we think about not necessarily kind of how patients are managed and what their journey looks like today from a first line, second line, third line perspective, but the way we approach development is how are patients going to be treated? What is their journey like with RCC going to be like in 2032, 2033, where more patients are likely to get adjuvant Pembro, so that frontline opportunity set is just functionally different than, say, how they're managed today or how they were managed two years ago. So that kind of dynamic changes. So, you know, certainly we're monitoring kind of everything that's going on competitively in the space. But we think we have some very competitive trials in LightSpark 33 with Merck. That's kind of that frontline post-adjuvant space. Yeah. And then 34, that later line space. And again, kind of, you know, we think the best way to view that lens is how are patients going to be managed in the future? And those two studies, I think, are really poised to define standards of care in a way that, you know, just doesn't exist today. Like, as an example, um... With Pembro now having a survival advantage, we're seeing more and more and more patients getting a Keytruda post-adjuvant or as part of their adjuvant care. Once their tumor does come back, though, the question is, what should they get? Right now, we think, Patients are likely getting Cabo more by default than anything because there's never really been a data set in that population. So, again, LightSpark 33 is poised to define a standard of care there. So, again, it's an example of kind of the approach that Exlexis takes in trying to be that leader in RCC, and we're going to continue to invest to be the leaders in RCC.

Ash Verma Analyst — UBS

Great. Okay, perfect. So just switching gears to the net indication, I know you've had a pretty successful launch here. Just what a function of the indolent disease is that the patient... This inflow into the funnel has been a little bit slower in the last couple of quarters. You have previously outlined this as roughly $400 million in terms of the peak sales opportunity. Do you think that is still a sustainable goal?

Andrew Peters Head of Investor Relations

Yeah, so there are a couple dynamics there. I think the first is, you know, we've said that the net market, that second line or later line, oral net market, is probably about a billion dollars TAM. And what we're going to do is try and fight for every single market share point of that that we can. You know, one, the data, the cabinet data certainly speak for themselves in terms of the potential positive impact in patients' lives. But two, given that it's a largely generic market, our share of voice is something that is particularly high and kind of has enabled us to really grab that kind of accelerated share. As it relates to kind of that temporal aspect of the launch that you talked about, how PJ outlined it on the last second two earnings calls ago, it's more of kind of a temporal dynamic in what the shape of the launch curve looks like, and it's not necessarily where that destination is. It's probably more of how we get there, and really what that is is a function of the nature of the net patient's journey again. So if you think about a normal, you know, lung cancer or something, patients come in, say, every three months for a scan to see is their tumor continuing to shrink, staying the same size, or unfortunately growing. And if it's growing, kind of a treatment decision is made at that time to, you know, switch to a new therapy, look at a new dose, you know, one of those things. Because NET is a more indolent disease, that scan interval, because the tumor is less aggressive in how it grows, can be longer, four, five, six months, potentially longer. So that opportunity set, if the patient's tumor is growing, to kind of come on to a new therapy is just temporarily right-shifted. And similarly, because the disease isn't as aggressive, what we're finding is especially in, say, some pockets of the commercial, of the community landscape, you know, treatment decision is something like, let's put you on Cabo. But before that, why don't you wash out for a month or so from your previous therapy, recover, get stronger, because all of these. Anti-cancer therapies, unfortunately, do come with some side effects. So again, you know, our market share data, new patient share data that we've outlined would certainly suggest that we're capturing those patients. It's just the time course of when they come on to therapy, you know, temporally is a little bit right shifted. And so our view, you know, kind of that aspirational goal number stays the same, just the shape and how we get there is maybe a little different.

Ash Verma Analyst — UBS

Perfect. Okay, great. That's great. And then one more aspect to Cabo has been just around the 340B impact to pricing. So yeah, like they're sort of like similar, I guess, on the veins of just a little bit more sporadic in terms of the impact to the, you know, the recently quarterly sales number. Has that sort of variability died down now? Just like going forward, what should we assume?

Andrew Peters Head of Investor Relations

Yeah, I mean, you know, it's funny. 340B is a dynamic that's not an ex-Alexis issue. It's frankly an industry issue. You know, the last data that I've seen is it's functionally a, you know, $80 to $100 billion wealth transfer from the manufacturers to the hospitals. And, um... You know, the industry collectively is, you know, trying to figure out how those dynamics work. And each company, ex-Alexis included, is also trying to, you know, figure out how do we best manage our business. And so you mentioned kind of the variability. I think, you know, we call it choppiness or some function like that. But the analogy I always like to think about is it's kind of a tennis match where the manufacturers do something, the hospitals do something, the 340B. You know, entities do something, we do something. And so it's kind of this back and forth. And the variability or choppiness or whoever, kind of depends on where we are in that relative back and forth. Every company implements kind of their own little. Um, strategies around how to ensure that the 340B program is being appropriately used. And so that kind of influences some of it, you know, obviously there's some seasonal dynamics, there's some calendar seasonal dynamics, there's just a lot of, you know, kind of back and forth. So again, we give annual guidance, not quarterly guidance, in part because we think that allows us to have the best kind of sense of what we'll shake out over the course of the year. Then you layer on kind of the intra-quarter choppiness that we and everyone see.

Ash Verma Analyst — UBS

Great. Okay. And just one more question on Cabo before we go to Zanza. So, yeah, good to see the settlement with Azureity. I know there is another just competitor out there, Handa. Would sort of the same dynamic apply for this competitor as they are trying to enter the market?

Andrew Peters Head of Investor Relations

Yeah, I mean, again, kind of don't want to get in ahead of any potential legal strategy dynamics. But the way that I think about Cabo and whether it's 340B or real generics. We managed the business with January 1st, 2031, as kind of the best guess on when a generic Cabo is going to be available. Beyond that, like any successful product, we're continuing to face. Legal challenges, and my visualization of it is there's a lot of balls in the air that we're juggling, but we have a pretty good sense of them, and we're kind of handling them as they come in. So, yeah, that's, that's it.

Ash Verma Analyst — UBS

Got it.

Andrew Peters Head of Investor Relations

Okay, great.

Ash Verma Analyst — UBS

Okay, so yeah, like, let's talk about Zanzalitinib. So, just maybe on the CRC approval, just heading into the decision for this Zanza plus Cetizo in third line plus opportunity. I mean, can you kind of frame on potential label scenarios here? I know, based on how the data has played out, so you had, like, the ITD population, which was positive, the NLM subgroup didn't really hit for whatever reason, but is this, like, are you confident that you would get a full label? And the reason why I ask this, like, there's some investors who think that, like, there's some gray area there, but actually FDA doesn't give approval based on the, you know, the presence or absence of metastasis in an individual organ. It's very, very rare to see that, like one to Kaiser is one example of it, but I haven't seen any of that. But just, yeah, like help us understand, you know, as you're getting towards the potential label scenarios, what that might entail.

Andrew Peters Head of Investor Relations

Yeah, so kind of for a little bit of background for those who aren't familiar, you And when we designed and ran the 303 study, it was really, you know, again, we wanted to be on the cutting edge of how patients are treated, and our observation had been, if you looked at, you know, the… Five or so prior studies that had looked at, say, checkpoints in this third-line-plus setting, there seemed to be a potentially differentiated benefit in patients without liver metastases. And so we designed the study to kind of look both at an ITT basis as well as that non-LiverMet group. Again, you know, one of the challenges with kind of post-talk, really empiric data, not necessarily mechanism-related data, turns out that non-LiverMet dynamic is just probably less of a relevant point, at least when you take a drug like Zanza, which, you know, the 303 data showed on an ITT basis that patients live longer if they take Zanza-Tezo relative to the standard of care. So that non-LiverMet group is probably less relevant, at least in our combination. As it relates to kind of this label issue, again, don't want to really speculate on it. But, you know, one, the ITT population, which is the study population that we filed on, was inclusive of both LiverMet and non-LiverMet patients. The dynamic that you're talking about where, you know, there is kind of a more selected patient population, that tends to come out of instances where there's a particular subgroup driving a lot of efficacy. I think the most prominent one or common one that comes to mind is the PARPs in kind of this BRCA population versus HRD versus, you know, all comers, where that BRCA mutant population really drove the efficacy overall. If you look at the 303 data and the forest plots, it's this consistency of effect across all of the different subgroups, you know, NLM, liver mets, prior avastin, you know, pretty much every way you could look at the data, there's this consistency of effect, and that's actually something that really kind of jumps out when we do market research with KOLs and kind of ad boards and stuff. That's something that I think differentiates the combination versus some of the other options out there for patients. And so, you know, we're excited about the potential approval. It's going to be kind of that foundation for Zanza that we're going to build on from there, not only in CRC because we have a couple of other. Studies ongoing there, but kind of the ZANSA development program in general.

Ash Verma Analyst — UBS

Great. Okay, perfect. So yeah, and then just on the market size here, so the latest earnings call, you outlined that there are roughly 23,000 patients, right? So just bear with me. I have been looking at this for a while, maybe for a long time, and I think some of the prior data Yeah, because that you have presented on this market opportunity, like if I go back like next three, like last three years, we've seen that this number was 27,000 to 31,000. So I guess I saw the latest is 23,000. I'm more trying to understand, is that like a firm assumption? Is there some variability around as you're getting close to the?

Andrew Peters Head of Investor Relations

Yeah, so I think you're kind of maybe reading into it a little bit incorrectly there. So, you know. the What we've done is we've kind of said we think it's about a billion five market, just TAM. The numbers you talked about, I think you're getting into drug treated versus drug treatable, and then 2025 or 2026 patients and 2035 patients. So kind of the way we view the world when we really dig in from a market research perspective and kind of that patient funnel, the epi changes over time. So obviously, there's some differences between how many patients now versus how many patients in the future. And then there's drug treatable versus drug treated, which are kind of two different cuts of that same data. So I think what you're referring to is probably more of those dynamics than anything. We've been pretty consistent about it being a billion five market in general. And again, our job is going to be to fight for every market share point we can within that segment. Yeah.

Ash Verma Analyst — UBS

So the billion five is the whole time multiplied by what the branded pricing would be. Is that okay? So you would take a share of that market?

Andrew Peters Head of Investor Relations

Yeah, yeah, yeah. So again, kind of for background folks, maybe less familiar, You know, one of the interesting things about CRC and later line CRC is that given that it's much more community-based than academic kind of KOL-based, market share is a little bit more fragmented than I think many people think. About a third of patients receive kind of that sunlight regimen, a third get a TKI, and then a third kind of, you know, chemo and a bunch of other stuff. And so when we talk about TAM, you know, same methodology in NETS, as we look at drug-treated patients. Uh, times, you know, the math is pretty simple drug treated patients. Assumed duration and then assumed contemporary price. So that's kind of that billion five that we think is a good north star, so to speak, for us to kind of go in and try and take as much share as we can.

Ash Verma Analyst — UBS

Yeah. Just in terms of the launch opportunity, yeah, what type of launch prep do you have going on for this? And yeah, I guess the community launches typically, like from what I've seen, can be a little bit gradual compared to, let's say, more academic type settings. So when you think about that market dynamic and then the current market composition around the sunlight or the TKI, chemo, where do you think you would take share from to begin with?

Andrew Peters Head of Investor Relations

Yeah, so our goal is to kind of take share across all of those segments. You know, certainly we think that we have a very compelling data set, and really that's what drives use in oncology is the data. Um, but when you layer on, you know, say factors, like I mentioned before, um, efficacy, despite prior avastin use, which is kind of a, one of the factors that say impacts like, you know, the sunlight regimen where, you know. Given that... Their data seem to show that patients do a little worse if they've received prior Avastin, with 80-plus percent of patients receiving one or two courses of Avastin prior to that third-line-plus setting. You know, the real-world implications, say, in the U.S., at least, are challenged there. Then, you know, again, a lot of these patients will have been on chemo for their first line and second line, and so Zanzotezo provides kind of this chemo-free option. And then the third one that we've certainly talked about that kind of tends to come up again and again in these ad boards and market research, et cetera, is kind of this checkpoint-containing dynamic. You know, as we move towards the community, you know, see one of these things where patients will be out watching the Super Bowl or, you know, some big event, and they'll see commercials for Keytruda or Pembro or Atezo or all of these and go into their oncologist and say, hey. Is this something that could be, that I could get for my cancer? And historically, the answer has been, unfortunately, for your tumor type, this sort of drug is not available. But 303 potentially enable that. And given that these community docs don't just focus on CRC, where the checkpoints haven't been used historically. That they see many different types of cancers, the level of familiarity, they're already writing scripts for a Tezo or a Keytrude or a Nivo, et cetera. So it's just a little bit of a different dynamic there. And so you take that, then you layer on the fact that we upsized our commercial organization earlier this year, in part to kind of continue to accelerate the net launch, but again, kind of have those boots on the ground, so to speak, ahead of the Zanza launch, given the overlap in those prescriber So it's one that we think we're particularly well set up for, and we're going to be ready kind of day one post-approval.

Ash Verma Analyst — UBS

Great. Awesome. I'll just open it up in the audience as well, if you have any questions, anybody. Otherwise, I have a few more that I'll ask. So maybe just on the non-clear cell RCC, so this trial, I mean, it's been delayed a few times, which is kind of like a positive signal, right? As you think about the, you know, the readout here, just if you can kind of remind the audience, so you're expecting a 1Q readout based on the events that are accruing? Is that, like, are you certain and getting to a reasonable amount of precision on that readout?

Andrew Peters Head of Investor Relations

Yeah, I mean, you know, it's an event-based endpoint, so, you know, literally we're counting events as they're coming in, And I think Dana talked about it on the last call. Based on kind of, you know, the events, we're expecting clinical cutoff shortly. And, you know, once you hit clinical cutoff, clean the data, et cetera, then you top line it. And so that's what gives us confidence around that 1Q. You know, if we see clinical cutoff around year end, that's what's driving that 1Q timing.

Ash Verma Analyst — UBS

Could that come at ASCOGI or at the conference?

Andrew Peters Head of Investor Relations

Can't speculate on when. I mean, the honest answer is it's going to take however long it takes to kind of clean the data, get the database ready to kind of. Get that envelope open and see the data and top line it. So 1Q is our best guess.

Ash Verma Analyst — UBS

Got it. Okay. And then just in terms of the, you know, the benchmarks here, particularly for the control arm. Yeah, I know some of the student data that exists from before is pretty old. Could there be a surprise in the control arm here?

Andrew Peters Head of Investor Relations

Yeah, I can't speculate on data, but, you know, I think you called out one of the dynamics that I think is somewhat unique in non-clear cells, just there's not great data across the board. You know, if you go back to when we were designing the study, one of the things that candidly surprised me is that there had never been a phase three study in this setting. And so we have a chance to really kind of plant a flag in the ground and define a standard of care. Again, you know, this theme that I had mentioned earlier in our conversation. And so it's really a chance to say with level one evidence in a large global randomized study, this is the standard of care. Whereas right now, treatment choices are really driven by single arm, unrandomized, relatively small phase two studies and NCCN guidelines. So we have a chance to define with level one evidence what the standard of care and non-clear cell RCC should be. And it, again, kind of provides that next step in the foundation of Zanza that as we look out, you know, what the next several years look like for us, it's really going to be about that breadth of opportunity with Zanza, not only the seven pivotal studies on wave one, but wave two coming in. And so as we see the company transitioning from Cabo to multi-franchise to Zanza to kind of what's next, that's kind of that growth trajectory that we're looking towards.

Ash Verma Analyst — UBS

Yeah. Great. With that, we are out of time. So I think you're good.

Andrew Peters Head of Investor Relations

All right.

Ash Verma Analyst — UBS

Yeah. Thank you so much for this. It was super helpful.

Analyst Q&A · 1 question
Full-screen source Call document